2021
The relationship of plasma antioxidant levels to semen parameters: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial
Knudtson JF, Sun F, Coward RM, Hansen KR, Barnhart KT, Smith J, Legro RS, Diamond MP, Krawetz SA, Zhang H, Usadi R, Baker VL, Santoro N, Steiner AZ. The relationship of plasma antioxidant levels to semen parameters: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Journal Of Assisted Reproduction And Genetics 2021, 38: 3005-3013. PMID: 34455507, PMCID: PMC8609082, DOI: 10.1007/s10815-021-02301-2.Peer-Reviewed Original ResearchConceptsPlasma antioxidant levelsLive birthsClinical trialsSemen parametersAntioxidant levelsVitamin ERank sum testSecondary analysisClinical outcomesNormal rangeBaseline plasma valuesVitamin E levelsWilcoxon rank sum testMale fertilityConclusionsAmong menPrimary endpointDNA fragmentationResultsAt baselineSerum levelsFertility centerE levelsMethodsThis studyMale infertilityFertility outcomesPlasma valuesMale vitamin D status and male factor infertility
Banks N, Sun F, Krawetz SA, Coward RM, Masson P, Smith JF, Trussell JC, Santoro N, Zhang H, Steiner AZ. Male vitamin D status and male factor infertility. Fertility And Sterility 2021, 116: 973-979. PMID: 34289935, PMCID: PMC8561776, DOI: 10.1016/j.fertnstert.2021.06.035.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, SpontaneousAdultBiomarkersClomipheneDietary SupplementsDouble-Blind MethodFemaleFertilityFertility Agents, FemaleHumansInfertility, MaleInsemination, Artificial, HomologousLive BirthMalePregnancyPregnancy RateProspective StudiesRisk FactorsSemenSemen AnalysisTime FactorsTreatment OutcomeUnited StatesVitamin DVitamin D DeficiencyConceptsVitamin D deficiencyLive birth rateMale factor infertilityD deficiencyFactor infertilityD levelsSemen parametersMild male factor infertilityMale partnersVitamin D levelsVitamin D statusRate of miscarriageFemale partnersSperm concentrationBirth rateClinical pregnancyClomiphene citrateD statusDNA fragmentationCumulative pregnancySperm DNA fragmentationVitamin DFertility centerIntrauterine inseminationMonth 4
2020
Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth
Engmann L, Sun F, Legro RS, Diamond MP, Zhang H, Santoro N, Bartlebaugh C, Dodson W, Estes S, Ober J, Brzyski R, Easton C, Hernandez A, Leija M, Pierce D, Robinson R, Awonuga A, Cedo L, Cline A, Collins K, Krawetz S, Puscheck E, Singh M, Yoscovits M, Barnhart K, Coutifaris C, Lecks K, Martino L, Marunich R, Snyder P, Alvero R, Comfort A, Crow M, Schlaff W, Casson P, Hohmann A, Mallette S, Christman G, Ohl D, Ringbloom M, Tang J, Bates G, Mason S, DiMaria N, Usadi R, Lucidi R, Rhea M, Baker V, Turner K, Trussell J, DelBasso D, Huang H, Li Y, Makuch R, Patrizio P, Sakai L, Scahill L, Taylor H, Thomas T, Tsang S, Yan Q, Zhang M, Haisenleder D, Lamar C, DePaolo L, Herring A, Redmond J, Thomas M, Turek P, Wactawski-Wende J, Rebar R, Cato P, Dukic V, Lewis V, Schlegel P, Witter F. Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth. Human Reproduction 2020, 35: 2819-2831. PMID: 33190149, PMCID: PMC8453415, DOI: 10.1093/humrep/deaa232.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeClinical trial protocolMedicine clinical trialsU10 HD055942U10 HD38998Baseline characteristicsTrial protocolClinical trialsLive birthsPolycystic Ovary Syndrome IIU10 HD38992U10 HD39005U10 HD27049STUDY FUNDING/COMPETINGMultiple Intrauterine GestationsStudy protocol adherenceUS multicenter trialRegular ovulatory cyclesClinical trial findingsPolycystic ovarian morphologyPARTICIPANTS/MATERIALSROLE OF CHANCELower household incomeAfrican AmericansAspects of adherenceAndrogenicity and fertility treatment in women with unexplained infertility
Wang ET, Diamond MP, Alvero R, Casson P, Christman GM, Coutifaris C, Hansen KR, Sun F, Legro RS, Robinson RD, Usadi RS, Pisarska MD, Santoro NF, Zhang H, Network I. Androgenicity and fertility treatment in women with unexplained infertility. Fertility And Sterility 2020, 113: 636-641. PMID: 32192596, PMCID: PMC7088440, DOI: 10.1016/j.fertnstert.2019.10.034.Peer-Reviewed Original ResearchConceptsLive birth rateBody mass indexUnexplained infertilityClinical pregnancyMass indexPregnancy lossClinical markersLive birthsAndrogenic activityFree androgen index valuesHigher body mass indexMultivariable logistic regression modelMultiple Intrauterine GestationsNormal uterine cavityHigh waist circumferenceOvarian stimulation treatmentPatent fallopian tubesBirth rateLogistic regression modelsAndrogen markersSerum TTOvarian stimulationRegular mensesInfertility populationIntrauterine gestation
2019
Lower antimüllerian hormone is associated with lower oocyte yield but not live-birth rate among women with obesity
Vitek W, Sun F, Baker VL, Styer AK, Christianson MS, Stern JE, Zhang H, Polotsky AJ. Lower antimüllerian hormone is associated with lower oocyte yield but not live-birth rate among women with obesity. American Journal Of Obstetrics And Gynecology 2019, 222: 363.e1-363.e7. PMID: 31589862, PMCID: PMC8022853, DOI: 10.1016/j.ajog.2019.09.046.Peer-Reviewed Original ResearchConceptsNormal body mass indexAntimüllerian hormone levelsLower antimüllerian hormoneBody mass indexLower oocyte yieldLive birth rateAntimüllerian hormoneLow ovarian reserveOocyte yieldMass indexHormone levelsOvarian reserveBody mass index 18.5Low antimüllerian hormone levelsAssisted Reproductive Technology Clinic Outcome Reporting System databaseLower live birth ratesClass 3 obesitySerum antimüllerian hormoneClass 1 obesityClass 2 obesityNumber of oocytesSmall antral folliclesReporting System databaseNormal BMIRetrospective cohort